S. Sandhu

发表

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

D. Schadendorf, P. Ascierto, P. Queirolo, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prostate cancer

R. Bristow, H. Beltran, C. Moore, 2021, The Lancet.

Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

D. Schadendorf, S. Puig, P. Ascierto, 2022, European journal of cancer.

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.

A. Hauschild, S. Puig, R. Fisher, 2021, European journal of cancer.

LBA46 Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial

P. Ascierto, A. Eggermont, M. Mandalà, 2020 .

Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma.

D. Schadendorf, P. Ascierto, A. Eggermont, 2022, NEJM evidence.

Adjuvant therapy for stage II melanoma: the need for further studies.

C. Garbe, M. Mandalà, G. Long, 2023, European journal of cancer.

Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

D. Schadendorf, P. Ascierto, C. Blank, 2023, European journal of cancer.

The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma.

G. McArthur, M. Shackleton, S. Sandhu, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Management of resected stage III/IV melanoma with adjuvant immunotherapy.

G. Long, A. Menzies, M. Carlino, 2021 .

Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.

S. Dawson, M. Dawson, N. Dhomen, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab

D. Mallardo, E. Simeone, P. Lorigan, 2023, Journal of Translational Medicine.

Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results

P. Ascierto, M. Sznol, H. Gogas, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma in Patients with Concomitant Chronic Lymphocytic Leukemia.

J. McQuade, J. Wargo, E. Keung, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.

G. Hospers, W. V. van Houdt, A. Menzies, 2024, Journal of Clinical Oncology.

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy.

R. Dummer, S. Patel, C. Blank, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.

C. Coens, A. van den Eertwegh, V. Atkinson, 2024, The Lancet. Oncology.

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

P. Ascierto, G. Hospers, J. Haanen, 2024, The New England journal of medicine.

Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab

A. van den Eertwegh, N. Khushalani, A. Chhibber, 2024, NPJ precision oncology.